CRC Risk Down With ACEi, Angiotensin Receptor Blocker UseLast Updated: July 06, 2020. The use of angiotensin converting enzyme inhibitors and angiotensin receptor blockers is associated with lower risk of colorectal cancer risk that develops within three years after index colonoscopy, according to a study published online July 6 in Hypertension.
MONDAY, July 6, 2020 (HealthDay News) -- The use of angiotensin converting enzyme (ACE) inhibitors and angiotensin receptor blockers is associated with lower risk of colorectal cancer risk that develops within three years after index colonoscopy, according to a study published online July 6 in Hypertension.
Ka Shing Cheung, M.B.B.S., from the University of Hong Kong, and colleagues examined the association between use of ACE inhibitors and angiotensin receptor blockers and colorectal cancer risk after a negative baseline colonoscopy among patients aged ≥40 years who underwent colonoscopy between 2005 and 2013. Data were included for 187,897 eligible patients, of whom 16.4 percent were ACE inhibitor/angiotensin receptor blocker users.
The researchers found that between six and 36 months after index colonoscopy, 854 patients (0.45 percent) developed colorectal cancer. Reduced risk of colorectal cancer that developed less than three years after index colposcopy (adjusted hazard ratio, 0.78; 95 percent confidence interval, 0.64 to 0.96) but not more than three years (adjusted hazard ratio, 1.18; 95 percent confidence interval, 0.88 to 1.57) was seen in association with drug use. The investigators observed a 5 percent reduction in adjusted hazard ratio risk with every single year increase in drug use.
"Apart from side effects and contraindications, compelling indication is another factor to be considered in the choice of a particular antihypertensive medication," the authors write. "Our study provided additional insights into the potential chemopreventive effects of ACE inhibitors/angiotensin receptor blockers against colorectal cancer development, apart from their known cardiovascular and renal benefits."
Two authors disclosed financial ties to the pharmaceutical industry.
|Previous: Outcomes Similar for COVID-19 in Patients With, Without HIV||Next: Health Expenditures Considerable for Asthma, COPD in U.S. Workers|
Reader comments on this article are listed below. Review our comments policy.